Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Inclusion Criteria

• •Previously untreated primary mediastinal diffuse large B-cell lymphoma, CD20 positive.
• •Patients must have histological confirmation of the diagnosis (it is recommended that the immunohistochemical panel includes: CD45, CD20, CD30, CD15, CD10, BCL6, BCL2, MUM-1), and in addition have a dominant mass within the anterior mediastinum.
• •No evidence of extranodal disease outside the chest including spleen and bone marrow.
• •Age at least 18 years.
• •Fit to receive chemotherapy and radiotherapy with curative intent.
• •At least 6 courses of Rituximab should be administered
• •Able and willing to give informed consent, and to undergo staging including PET scanning
• •Willingness to comply with an appropriate contraceptive method in women of childbearing potential or men.
• •Histological diagnostic material available for review.